MX2019011743A - Derivados de tiocarbamato como inhibidores de a2a y metodos para su uso en el tratamiento de canceres. - Google Patents
Derivados de tiocarbamato como inhibidores de a2a y metodos para su uso en el tratamiento de canceres.Info
- Publication number
- MX2019011743A MX2019011743A MX2019011743A MX2019011743A MX2019011743A MX 2019011743 A MX2019011743 A MX 2019011743A MX 2019011743 A MX2019011743 A MX 2019011743A MX 2019011743 A MX2019011743 A MX 2019011743A MX 2019011743 A MX2019011743 A MX 2019011743A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- inhibitors
- treatment
- cancers
- oxo
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 5
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- CZWWCTHQXBMHDA-UHFFFAOYSA-N 3h-1,3-thiazol-2-one Chemical class OC1=NC=CS1 CZWWCTHQXBMHDA-UHFFFAOYSA-N 0.000 title 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D497/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms
- C07D497/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having oxygen and sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D497/14—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invención se refiere a compuestos de la Fórmula I (ver formula I) o sales o solvatos farmacéuticamente aceptables de los mismos. La invención se refiere además al uso de los compuestos de la Fórmula I como inhibidores de A2A. La invención también se refiere al uso de los compuestos de la Fórmula I para el tratamiento y/o prevención del cáncer. La invención también se refiere a un proceso para elaborar los compuestos de la Fórmula I.
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP17163781 | 2017-03-30 | ||
US201762565281P | 2017-09-29 | 2017-09-29 | |
EP17194084 | 2017-09-29 | ||
ARP180100778A AR111200A1 (es) | 2017-03-30 | 2018-03-28 | Derivados de tiocarbamato como inhibidores de a2a y métodos para usar en el tratamiento de cánceres |
PCT/EP2018/058301 WO2018178338A1 (en) | 2017-03-30 | 2018-03-30 | 2-oxo-thiazole derivatives as a2a inhibitors and compounds for use in the treatment of cancers |
Publications (1)
Publication Number | Publication Date |
---|---|
MX2019011743A true MX2019011743A (es) | 2020-01-20 |
Family
ID=61911575
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2019011743A MX2019011743A (es) | 2017-03-30 | 2018-03-30 | Derivados de tiocarbamato como inhibidores de a2a y metodos para su uso en el tratamiento de canceres. |
MX2022005298A MX2022005298A (es) | 2017-03-30 | 2019-09-30 | Compuestos intermediarios de sintesis de inhibidores de a2a. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2022005298A MX2022005298A (es) | 2017-03-30 | 2019-09-30 | Compuestos intermediarios de sintesis de inhibidores de a2a. |
Country Status (20)
Country | Link |
---|---|
US (3) | US10995101B2 (es) |
EP (2) | EP4112623A1 (es) |
JP (2) | JP7197558B2 (es) |
KR (2) | KR102640927B1 (es) |
CN (3) | CN110678472B (es) |
AU (1) | AU2018246355B2 (es) |
BR (1) | BR112019020421A8 (es) |
CA (1) | CA3058260A1 (es) |
DK (1) | DK3601296T3 (es) |
ES (1) | ES2926158T3 (es) |
HR (1) | HRP20221039T1 (es) |
HU (1) | HUE059990T2 (es) |
IL (2) | IL300149A (es) |
LT (1) | LT3601296T (es) |
MX (2) | MX2019011743A (es) |
PL (1) | PL3601296T3 (es) |
RS (1) | RS63557B1 (es) |
RU (1) | RU2019134724A (es) |
SI (1) | SI3601296T1 (es) |
TW (1) | TWI836960B (es) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111093666A (zh) | 2017-07-18 | 2020-05-01 | 诺维逊生物股份有限公司 | 1,8-萘啶酮化合物及其用途 |
AU2018302179A1 (en) | 2017-07-18 | 2020-02-13 | Nuvation Bio Inc. | Heterocyclic compounds as adenosine antagonists |
US11376255B2 (en) | 2018-09-11 | 2022-07-05 | iTeos Belgium SA | Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents |
AU2019337974A1 (en) * | 2018-09-11 | 2021-04-08 | iTeos Belgium SA | Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents |
US11427594B2 (en) | 2018-09-27 | 2022-08-30 | iTeos Belgium SA | Non brain penetrant A2A inhibitors and methods for use in the treatment of cancers |
JP2022517419A (ja) | 2019-01-18 | 2022-03-08 | ニューベイション・バイオ・インコーポレイテッド | アデノシンアンタゴニストとしてのヘテロ環式化合物 |
EP3911324A4 (en) | 2019-01-18 | 2022-08-17 | Nuvation Bio Inc. | 1,8-NAPHTHYRIDINONE COMPOUNDS AND THEIR USES |
CN114539265B (zh) * | 2022-03-02 | 2023-07-21 | 中山大学 | 靶向a2a的苯并咪唑并吡嗪-3-甲酰胺及其肿瘤免疫功能 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6448253B1 (en) | 1998-09-16 | 2002-09-10 | King Pharmaceuticals Research And Development, Inc. | Adenosine A3 receptor modulators |
US6921825B2 (en) | 1998-09-16 | 2005-07-26 | King Pharmaceuticuals Research & Development, Inc. | Adenosine A3 receptor modulators |
TWI288137B (en) * | 2000-05-26 | 2007-10-11 | Schering Corp | Adenosine A2a receptor antagonists |
WO2004092171A2 (en) * | 2003-04-09 | 2004-10-28 | Biogen Idec Ma Inc. | Triazolo[1,5-a]pyrimidines and pyrazolo[1,5-a]pyrimidines useful as a2a adenosin e receptor antagonists |
ES2342082T3 (es) * | 2004-04-21 | 2010-07-01 | Schering Corporation | Antagonistas de receptores a2a de adenosina de pirazolo(4,3-e)-1,2,4-triazolo(1,5-c)pirimidina. |
WO2007140181A2 (en) | 2006-05-26 | 2007-12-06 | King Pharmaceuticals Research And Development, Inc. | Combination therapy comprising an adenosine uptake inhibitor and a non-selective adenosine receptor antagonist |
US7691869B2 (en) * | 2007-03-30 | 2010-04-06 | King Pharmaceuticals Research And Development, Inc. | Pyrrolotriazolopyrimidine derivatives, pharmaceutical compositions containing them and methods of treating conditions and diseases mediated by the adenosine A2A receptor activity |
TW200914048A (en) | 2007-07-17 | 2009-04-01 | Combinatorx Inc | Combinations for the treatment of B-cell proliferative disorders |
US20110237599A1 (en) | 2010-03-10 | 2011-09-29 | Kalypsys, Inc. | Heterocyclic inhibitors of histamine receptors for the treatment of disease |
US9006177B2 (en) | 2010-09-24 | 2015-04-14 | Advinus Therapeutics Limited | Fused tricyclic compounds as adenosine receptor antagonist |
WO2012055015A1 (en) | 2010-10-26 | 2012-05-03 | Alberta Health Services | Combination comprising an atp analog and an adenosine receptor antagonist or a nucleobase/nucleoside analog for the treatment of cancer |
WO2012135084A1 (en) * | 2011-03-31 | 2012-10-04 | Merck Sharp & Dohme Corp. | METABOLITES OF 2-(FURAN-2-YL)-7-(2-(4-(4-(2-METHOXYETHOXY)PHENYL)PIPERAZIN-1-YL)ETHYL)-7H-PYRAZOLO[4,3-e][1,2,4]TRIAZOLO[1,5-c]PYRIMIDIN-5-AMINE AND THEIR UTILITY AS ADENOSINE A2a RECEPTOR ANTAGONISTS |
EP3570844B1 (en) | 2017-01-20 | 2023-09-06 | Arcus Biosciences, Inc. | Azolopyrimidine for the treatment of cancer-related disorders |
TWI801372B (zh) * | 2017-03-30 | 2023-05-11 | 比利時商艾特歐斯比利時有限公司 | 作為a2a抑制劑的硫胺甲酸酯衍生物以及用於癌症治療的方法 |
JP7391022B2 (ja) | 2017-12-19 | 2023-12-04 | インペティス・バイオサイエンシーズ・リミテッド | がんの処置のための医薬組成物 |
AU2019337974A1 (en) | 2018-09-11 | 2021-04-08 | iTeos Belgium SA | Thiocarbamate derivatives as A2A inhibitors, pharmaceutical composition thereof and combinations with anticancer agents |
US11427594B2 (en) | 2018-09-27 | 2022-08-30 | iTeos Belgium SA | Non brain penetrant A2A inhibitors and methods for use in the treatment of cancers |
WO2020065036A1 (en) | 2018-09-27 | 2020-04-02 | Iteos Therapeutics S.A. | Use of an inhibitor of an ent family transporter in the treatment of cancer and combination thereof with an adenosine receptor antagonist |
-
2018
- 2018-03-30 HR HRP20221039TT patent/HRP20221039T1/hr unknown
- 2018-03-30 CN CN201880034926.9A patent/CN110678472B/zh active Active
- 2018-03-30 EP EP22165965.9A patent/EP4112623A1/en active Pending
- 2018-03-30 MX MX2019011743A patent/MX2019011743A/es unknown
- 2018-03-30 PL PL18716193.0T patent/PL3601296T3/pl unknown
- 2018-03-30 RS RS20220794A patent/RS63557B1/sr unknown
- 2018-03-30 CN CN202211706953.0A patent/CN115873022A/zh active Pending
- 2018-03-30 DK DK18716193.0T patent/DK3601296T3/da active
- 2018-03-30 CA CA3058260A patent/CA3058260A1/en active Pending
- 2018-03-30 JP JP2020503355A patent/JP7197558B2/ja active Active
- 2018-03-30 SI SI201830747T patent/SI3601296T1/sl unknown
- 2018-03-30 HU HUE18716193A patent/HUE059990T2/hu unknown
- 2018-03-30 IL IL300149A patent/IL300149A/en unknown
- 2018-03-30 KR KR1020197031322A patent/KR102640927B1/ko active IP Right Grant
- 2018-03-30 ES ES18716193T patent/ES2926158T3/es active Active
- 2018-03-30 KR KR1020247005971A patent/KR20240027885A/ko active Application Filing
- 2018-03-30 BR BR112019020421A patent/BR112019020421A8/pt unknown
- 2018-03-30 AU AU2018246355A patent/AU2018246355B2/en active Active
- 2018-03-30 CN CN202211658370.5A patent/CN115991679A/zh active Pending
- 2018-03-30 RU RU2019134724A patent/RU2019134724A/ru not_active Application Discontinuation
- 2018-03-30 TW TW112113401A patent/TWI836960B/zh active
- 2018-03-30 LT LTEPPCT/EP2018/058301T patent/LT3601296T/lt unknown
- 2018-03-30 EP EP18716193.0A patent/EP3601296B1/en active Active
-
2019
- 2019-03-14 US US16/354,022 patent/US10995101B2/en active Active
- 2019-09-26 IL IL269710A patent/IL269710B2/en unknown
- 2019-09-30 MX MX2022005298A patent/MX2022005298A/es unknown
-
2020
- 2020-08-14 US US16/993,897 patent/US20210198281A1/en not_active Abandoned
-
2022
- 2022-09-21 US US17/949,595 patent/US20230159564A1/en active Pending
- 2022-12-15 JP JP2022199962A patent/JP2023027282A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022005298A (es) | Compuestos intermediarios de sintesis de inhibidores de a2a. | |
MY196836A (en) | Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (dub) inhibitors | |
MX2020012165A (es) | Derivados de bencimidazol como inhibidores de tirosina cinasa erbb para el tratamiento del cancer. | |
TN2016000501A1 (en) | Pyrrolidine-2,5-dione derivatives, pharmaceutical compositions and methods for use as ido1 inhibitors. | |
MX2020010496A (es) | Inhibidores de desmetilasa-1 especifica de lisina. | |
MD4800C1 (ro) | Compuşi de aminopirimidinil ca inhibitori de JAK | |
MX2017013797A (es) | Inhibidor de janus quinasa. | |
MA39986A (fr) | Dérivés de purine en tant qu'inhibiteurs de cd73 pour le traitement du cancer | |
MX2016017030A (es) | Inhibidores de cinasa de interaccion con proteina cinasa activada por mitogeno (mnk) y metodos relacionados con los mismos. | |
MX2017002824A (es) | Inhibidores demetilasa-1 especifica de lisina. | |
MX2018015094A (es) | Derivados de carbonucleosidos sustituidos utiles como agentes antineoplasicos. | |
MX2017000179A (es) | Inhibidores de demetilasa-1 especifica de lisina. | |
MY197626A (en) | Dihydroimidazopyrazinone derivatives useful in the treatment of cancer | |
TN2012000622A1 (en) | Combinations of kinase inhibitors for the treatment of cancer | |
MX2020010900A (es) | Inhibidores de demetilasa-1 especifica de lisina. | |
MX2017000170A (es) | Inhibidores de demetilasa-1 especifica de lisina. | |
MX2018001992A (es) | Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa. | |
EA033238B1 (ru) | Новые производные тиенопиримидина в качестве ингибиторов nik | |
MX2018004664A (es) | Antagonistas de ep4. | |
MX2019006843A (es) | Inhibidor de cdk4/6. | |
PH12017500007A1 (en) | Quinolizinone derivatives as p13k inhibitors | |
MX2015010619A (es) | Cis-morfolinona y otros compuestos como inhibidores de mdm2 para el tratamiento del cancer. | |
MX2017012123A (es) | Combinaciones de un compuesto inhibidor de fosfoinositido 3-cinasa y un compuesto inhibidor de cdk4/6 para el tratamiento del cancer. | |
MX2022000390A (es) | Derivados macrociclicos espirociclicos como inhibidores de mcl-1. | |
PH12020551343A1 (en) | 7-substituted sulfonimidoylpurinone compounds and derivatives for the treatment and prophylaxis of liver cancer |